EyePoint Pharmaceuticals will have multiple presentations at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting, taking place May 3-7 in Denver, Colorado.
The presentation details include:
- Poster Presentation: COMO and CAPRI trial design: Pivotal phase 3 non-inferiority studies of EYP-1901 vs on-label aflibercept in diabetic macular edema, Presenter: Hasenin Al-khersan
- Paper Presentation: VERONA phase 2 clinical trial of bioerodible EYP-1901 (vorolanib intravitreal insert) versus aflibercept for diabetic macular edema (DME): Visual, anatomic, and angiographic outcomes, Presenter: Katherine E. Talcott
- Poster Presentation: DAVIO 2 phase 2 trial of bioerodible EYP-1901 (vorolanib intravitreal insert) for wet age-related macular degeneration: Results in subgroup that met LUGANO/LUCIA phase 3 inclusion criteria, Presenter: Dilraj Grewal
- Paper Presentation: DAVIO 2 Phase 2 Trial: Vision Outcomes with Bioerodible EYP-1901 (vorolanib intravitreal insert) Versus Aflibercept in Wet Age-Related Macular Degeneration (wAMD), Presenters: Akshay Thomas, Christiana Dinah
- Poster Presentation: Development of EYP-1901, a bioerodible intravitreal (IVT) insert for sustained release of the tyrosine kinase inhibitor (TKI) vorolanib for retinal exudative disease, Presenters: Jeff Lynch, Christopher Crean, Marcia Sellos-Moura
- Poster Presentation: Vorolanib inhibition of IL-6 signaling: A novel multi-mechanism of action for EYP-1901 in retinal exudative diseases, Presenters: Rishi P. Singh, Jeff Lynch, Marcia Sellos-Moura
